Enhanced Th2 immunity after DNA prime-protein boost immunization with amyloid β (1-42) plus CpG oligodeoxynucleotides in aged rats

Neuroscience Letters

Volumn 436, Issue 2, 2008, Pages 219-222

  Subramanian, Sarada ^a   Divya Shree, A N ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

Adjuvant; Alzheimer's disease; Oligodeoxynucleotides; Prime boost strategy; Th2 response

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; CPG OLIGODEOXYNUCLEOTIDE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2B; PLASMID DNA;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; NONHUMAN; PRIORITY JOURNAL; RAT; TH1 CELL; TH2 CELL;

AGING; AMYLOID BETA-PROTEIN; ANIMALS; ANTIBODIES; DNA PRIMERS; DRUG ADMINISTRATION ROUTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNIZATION; OLIGODEOXYRIBONUCLEOTIDES; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY; TH2 CELLS; TIME FACTORS;

EID: 41949139857     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2008.03.024     Document Type: Article

References (42)

1. Agadjanyan M.G., Ghochikyan A., Petrushina I., Vasilevko V., Movsesyan N., Mkrtichyan M., Saing T., and Cribbs D.H. Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from ß-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J. Immunol. 174 (2005) 1580-1586
2. Bayer A.J., Bullock R., Jones R.W., Wilkinson D., Paterson K.R., Jenkins L., Millais S.B., and Donoghue S. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology 64 (2005) 94-101
3. Cribbs D.H., Ghochikyan A., Vasilevko V., Tran M., Petrushina I., Sadzikava N., Babikyan D., Kesslak P., Kieber-Emmons T., Cotman C.W., and Agadjanyan M.G. Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with ß-amyloid. Int. Immunol. 15 (2003) 505-514
4. Dodel R.C., Hampel H., and Du Y. Immunotherapy for Alzheimer's disease. Lancet Neurol. 2 (2003) 215-220
5. Ferrer I., Boada Rovira M., Sanchez Guerra M.L., Rey M.J., and Costa Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol. 14 (2004) 11-20
6. Ghochikyan A., Vasilevko V., Petrushina I., Movsesyan N., Babikyan D., Tian W., Sadzikava N., Ross T.M., Head E., Cribbs D.H., and Agadjanyan M.G. Generation and characterization of the humoral immune response to DNA immunization with a chimeric ß amyloid-interleukin-4 minigene. Eur. J. Immunol. 33 (2003) 3232-3241
7. Ghochikyan A., Mkrtichyan M., Petrushina I., Movsesyan N., Karapetyan A., Cribbs D.H., and Agadjanyan M.G. Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-Aβ antibody response with alum to quil A adjuvant switch. Vaccine 24 (2006) 2275-2282
8. Ghochikyan A., Petrushina I., Lees A., Vasilevko V., Movsesyan N., Karapetyan A., Agadjanyan M.G., and Cribbs D.H. Aβ-immunotherapy for Alzheimer's disease using mannan-amyloid-beta peptide immunoconjugates. DNA Cell Biol. 25 (2006) 571-580
9. Gilman S., Koller M., Black R.S., Jenkins L., Griffith S.G., Fox N.C., Eisner L., Kirby L., Boada Rovira M., Forette F., and Orgogozo J.M. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64 (2005) 1553-1562
10. Hacker H., Vabulas R.M., Takeuchi O., Hoshino K., Akira S., and Wagner H. Immune cell activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF) 6. J. Exp. Med. 192 (2000) 595-600
11. Hardy J., and Selkoe D.J. The Amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002) 353-356
12. 1-42 in young and aged canines: Antibody generation and characteristics, and effects on CSF and brain Aβ. Vaccine 24 (2006) 2824-2834
13. Hock C., Konietzko U., Sreffer J.R., Tracy J., Signorell A., Muller-Tillmanns B., Lemke U., Henke K., Moritz E., and Garcia E. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38 (2003) 547-554
14. Karande A.A., Velu N.K., and Adiga P.R. A monoclonal antibody recognizing the C-terminal region of chicken egg white riboflavin carrier protein terminates early pregnancy in mice. Mol. Immunol. 28 (1991) 471-478
15. Kim H.-D., Jin J.-J., Maxwell A., and Fukuchi K.-i. Enhancing Th2 immune responses against amyloid protein by a DNA prime-adenovirus boost regimen for Alzheimer's disease. Immunol. Lett. 112 (2007) 30-38
16. Klinman D.M., Yamshchikov G., and Ishigalsubo Y. Contribution of CpG motifs to the immunogenicity of DNA vaccines. J. Immunol. 158 (1997) 3635-3642
17. Klinman D.M., Barnhart K.M., and Conover J. CpG motifs as immune adjuvants. Vaccine 17 (1999) 19-25
18. Klinman D.M., Currie D., Gursel I., and Verthelyi D. Use of CpG oligodeoxynucleotides as immune adjuvants. Immol. Rev. 199 (2004) 201-216
19. Lemere C.A., Maron R., Spooner E.T., Grenfell T.J., Mori C., Desai R., Hancock W.W., Weiner H.L., and Selkoe D.J. Nasal A beta treatment induces anti-A beta antibody production and decreases cerebral amyloid burden in PD-APP mice. Ann. N. Y. Acad. Sci. 920 (2000) 328-331
20. Maier M., Seabrook T.J., and Lemere C.A. Modulation of the humoral and cellular immune response in Aβ immunotherapy by the adjuvants monophosphoryl lipid A (MPL), cholera toxin B subunit (CTB) and E. coli enterotoxin LT (R192G). Vaccine 23 (2005) 5149-5159
21. Masliah E., Hansel L., Adame A., Crews L., Bard F., Lee C., Seubert P., Games D., Kirby L., and Schenk D. Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 64 (2005) 129-131
22. Monsonego A., Maron R., Zota V., Selkoe D.J., and Weiner H.L. Immune hyporesponsiveness to amyloid-beta peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease. Proc. Natl. Acad. Sci. 98 (2001) 10273-10278
23. Muraguchi A., Hirano T., Tang B., Matsuda T., Horii Y., Nakajima K., and Kishimoto T. The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J. Exp. Med. 167 (1988) 332-344
24. Nicoll J.A., Wilkinson D., Holmes C., Steart P., Markham H., and Weller R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med. 9 (2003) 448-452
25. Orgogozo J.M., Gilman S., Dartigues J.F., Laurent B., Puel M., Kirby L.C., Jouanny P., Dubois B., Eisner L., Flitman S., Michael B.F., Boada M., Frank A., and Hock C. Subacute meningoencephalitis in a subset of patients with AD after Abeta 42 immunization. Neurology 61 (2003) 46-54
26. Pifer J., Hennes J.L., Lee J.M., and Witte P.L. Age-related differences in the immune response to immunization with human Abeta42 peptide. J. Gerontol. A Biol. Sci. Med. Sci. 57 (2002) B355-B358
27. Qu B., Rosenberg R.N., Li L., Boyer P.J., and Johnston S.A. Gene vaccination to bias the immune response to amyloid-β peptide as therapy for Alzheimer disease. Arch. Neurol. 61 (2004) 1859-1864
28. Rangan S.K., Liu R., Brune D., Planque S., Paul S., and Sierks M.R. Degradation of β-amyloid by proteolytic antibody light chains. Biochemistry 42 (2003) 14328-14334
29. Roman M., Martin-Orozco E., Goodman J.S., Nguyen M.D., Sato Y., Ronaghy A., Kornbluth R.S., Richman D.D., Carson D.A., and Raz E. Immunostimulatory DNA sequences function as T helper-1 promoting adjuvants. Nat. Med. 3 (1997) 849-854
30. Rosset M.B., Ballerini C., Gregoire S., Metharom P., Carnaud C., and Aucouturier P. Breaking immune tolerance to the prion protein using prion protein peptides plus oligodeoxynucleotide-CpG in mice. J. Immunol. 172 (2004) 5168-5174
31. Sato Y., Roman M., Tighe H., Lee D., Corr M., Nguyen M., Carson D.A., and Raz E. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 273 (1996) 352-354
32. Schenk D. Amyloid-β immunotherapy for Alzheimer's disease: the end of the beginning. Nat. Rev. Neurosci. 3 (2002) 824-828
33. Schenk D., Barbour R., Dunn W., Gordon G., Gradeja H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberurg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., and Seubert P. Immunization with amyloid-beta attenuates Alzheimer disease-like pathology in the PDAPP mouse. Nature 400 (1999) 173-177
34. Seabrook T.J., Thomas K., Jiang L., Bloom J., Spooner E., Maier M., Bitan G., and Lemere C.A. Dendrimeric Aβ1-15 is an effective immunogen in wildtype and APP-tg mice. Neurobiol. Aging 28 (2007) 813-823
35. Selkoe J.D., and Schenk D. Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Ann. Rev. Pharmacol. Toxicol. 43 (2003) 545-584
36. Subramanian S., and Divya Shree A.N. Expression, purification and characterization of a synthetic gene encoding human amyloid β (Aβ1-42) in Escherichia coli. Indian J. Biochem. Biophys. 44 (2007) 71-75
37. Thoelen S., Van Damme P., Mathei C., Leroux-Roels G., Desombere I., Safary A., Vandepapeliere P., Slaoui M., and Meheus A. Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. Vaccine 16 (1998) 708-714
38. 1-42. J. Neuroimmunol. 132 (2002) 49-59
39. R amyloid-β vaccine for immunotherapy of Alzheimer's disease. Vaccine 25 (2007) 3041-3052
40. Weiner H.L., Lemere C.A., Maron R., Spooner E.T., Grenfell T.J., Mori C., Issazadeh S., Hancock W.W., and Selkoe D.J. Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann. Neurol. 48 (2000) 567-579
41. Zfinkelman F.D., Holmes J., Katona I.M., Urban J.F., Beckmann M.P., Park L.S., Schooley K.A., Coffman R.L., Mossmann T.R., and Paul W.E. Lymphokine control of in vivo immunoglobulin isotype selection. Ann. Rev. Immunol. 8 (1990) 303-333
42. Zhang J., Wu X., Qin C., Qi J., Ma S., Zhang H., Kong Q., Chen D., Ba D., and He W. A novel recombinant adeno-associated virus vaccine reduces behavioural impairment and β-amyloid plaques in a mouse model of Alzheimer's disease. Neurobiol. Dis. 14 (2003) 365-379